HeartSciences (HSCS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Jun, 2026Executive summary
HeartSciences and Fortitude Mining Holdings entered into a definitive all-stock merger agreement, aiming to create a leading vertically integrated Zcash mining platform that will operate under the Fortitude brand and trade on Nasdaq under the ticker TUDE, with closing expected in H2 2026.
Fortitude will bring its vertically integrated Zcash mining operations, venture mining strategy, and diversified power portfolio to the public markets, leveraging its relationship with Digital Currency Group (DCG) as the largest shareholder.
The combined company targets significant expansion, aiming for 80 megawatts of owned capacity by year-end 2026 and continued focus on high-return opportunities in the Proof-of-Work ecosystem.
HeartSciences will continue to advance its AI-enabled ECG technology as a business unit within the combined entity, benefiting from improved capital access and operational focus.
Voting matters and shareholder proposals
HeartSciences shareholders will vote on the proposed merger and related matters at a special meeting, with a proxy statement to be filed and mailed to shareholders.
The transaction is subject to customary closing conditions, including shareholder approval and regulatory filings.
Board of directors and corporate governance
The combined company will be led by Fortitude’s current management team, with DCG remaining the largest and controlling shareholder.
Both boards unanimously approved the merger agreement.
Latest events from HeartSciences
- Fortitude and HeartSciences announce an all-stock merger, targeting completion in late 2026.HSCS
Proxy filing24 Jun 2026 - Vertically integrated Zcash miner leverages scale, DCG backing, and operational discipline for growth.HSCS
Investor presentation23 Jun 2026 - HeartSciences and Fortitude to merge, forming a leading public Zcash mining platform under DCG.HSCS
Proxy filing23 Jun 2026 - Expanded AI-ECG offerings, strong balance sheet, and regulatory progress set stage for growth.HSCS
Q4 20248 Jun 2026 - Net loss increased to $2.1 million as R&D costs rose and new financing was secured.HSCS
Q1 20258 Jun 2026 - AI-ECG platform advances, FDA submission nears, CMS reimbursement secured, no revenue, $4.1M cash.HSCS
Q2 20258 Jun 2026 - Net loss increased, cash reserves fell, and continued operations depend on new funding and FDA clearance.HSCS
Q3 20258 Jun 2026 - AI-ECG platform launch and regulatory progress set stage for 2026 commercialization.HSCS
Q4 20258 Jun 2026 - FDA breakthrough, new AI-ECG platform launch, and urgent capital needs amid ongoing losses.HSCS
Q1 20268 Jun 2026